Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

million and escalating royalties on sales commensurate with the current stage of development of the product if dirucotide (MBP8298) is commercialized. The completion of the licensing agreement with Lilly resulted in a one time payment of a $9.0 million licensing bonus to Corporation personnel, paid in February, 2008.

Financial Results

The consolidated net loss for the first quarter ended March 31, 2008 was $6.7 million or ($0.07) per share compared to a consolidated net loss of $12.9 million or ($0.17) per share for the first quarter of the previous year.

Revenue for the three months ended March 31, 2008 was $12.8 million compared to $nil for the first three months of the previous year. The revenue is the result of recognizing a portion of the upfront payment received on the completion of the licensing agreement with Eli Lilly and Company.

Total consolidated expenses for the three months ended March 31, 2008 were $22.2 million compared to $13.3 million for the first three months of the previous year.

Research and development expenses for the first quarter ended March 31, 2008 totaled $13.1 million compared to $10.3 million for the first quarter of the previous year. The increase of $2.8 million is primarily attributable to: a one time licensing bonus payment of $3.4 million to research and development personnel, a decrease in drug manufacturing costs of $1.4 million and a decrease in clinical trial expenses of $1.7 million. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion while the MAESTRO-02 and MAESTRO-03 trials increase in number of patients under treatment.

General and administrative expenses were $8.7 million for the three months ended March 31, 2008 compared to $2.6 million for the three months ended March 31, 2007. The increase is primarily attributable to: a one time licensing bonus payment of $5.6
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 Protea ... AG jointly announced today an update from their ... 3D InSight™ microtissues. In August 2014, Protea received ... scientific team for onsite training on the handling ... developed workflows for processing the 3D microtissues for ...
(Date:10/2/2014)... Wayne, NJ (PRWEB) October 02, 2014 At ... squeezed, Bel-Art Products has introduced a new kind ... New to market is the Scienceware® Squeeze Rite™ Wash ... the dip tube position within the bottle reduces the waste ... complete dispensing of those liquids. , “Easier to squeeze when ...
(Date:10/2/2014)... 2, 2014  CSSi ( www.CSSiEnroll.com ), the ... research industry, is pleased to announce its participation ... of October.  President Chris Trizna will ... in Clinical Trials New England conference sponsored by ... the annual Site Solutions Summit sponsored by the ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
Breaking Biology Technology:Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 3Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 4New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3
... Aug. 28 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the following conferences:, -- BioCentury,s ... 9:00 a.m. Eastern Time at the Millennium Broadway Hotel ... Conference on Wednesday, September 24,at 4:30 p.m. Eastern Time ...
... Exclusion of Venous Thromboembolism-, LEXINGTON, Mass., Aug. ... US Food and Drug Administration (FDA) has,granted 510(k) ... HemosIL D-Dimer,assay to exclude venous thromboembolism (VTE) in ... embolism (PE), when used in,conjunction with a clinical ...
... (ESA) has appointed the UK,s National Physical Laboratory (NPL) ... will lead a consortium to identify the next generation ... in future space missions. , "Advances in nanotechnology are ... Research Scientist in the nanomaterials group at NPL, who ...
Cached Biology Technology:Medivation Announces Participation in Upcoming Conferences 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... Prenatal exposure to tetrachloroethylene (PCE) in drinking water ... abruption, according to a new study led by ... , The study, published in the journal ... 1,019 unexposed pregnancies among 1,766 women in Cape ... late 1960s to the early 1980s by the ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... Autism Speaks applauds the consensus statement and recommendations ... disorders in children with autism spectrum disorders (ASD) released ... advancing physician awareness of unique challenges in the medical ... see the publication of these consensus recommendations. Autism Speaks, ...
... nerves are the likely origin of the Devil Facial Tumour ... an international team of scientists has discovered. Devil ... only Tasmanian devils and was first reported in 1996. It ... disease is characterised by large tumours, mostly on the face ...
... have new insight into the sex lives of the much-maligned ... deaths, according to a report published online on December 31st ... finding a partner of the right species type, male and ... harmony. Those tones are produced and varied based on the ...
Cached Biology News:Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3Nervous culprit found for Tassie devil facial tumor disease 2To a mosquito, matchmaking means 'singing' in perfect harmony 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: